

Simon Crouch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3844770/publications.pdf>

Version: 2024-02-01

41
papers

1,475
citations

471509

17
h-index

345221

36
g-index

42
all docs

42
docs citations

42
times ranked

3316
citing authors

#	ARTICLE	IF	CITATIONS
1	Cohort Profile Update: The Haematological Malignancy Research Network (HMRN) UK population-based cohorts. <i>International Journal of Epidemiology</i> , 2022, 51, e87-e94.	1.9	7
2	Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network. <i>Blood Advances</i> , 2022, 6, 5716-5731.	5.2	12
3	Application of the LymphGen classification tool to 928 clinically and genetically characterised cases of diffuse large B cell lymphoma (DLBCL). <i>British Journal of Haematology</i> , 2021, 192, 216-220.	2.5	28
4	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. <i>Blood Advances</i> , 2021, 5, 3066-3075.	5.2	12
5	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2020, 105, 632-639.	3.5	35
6	Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. <i>Haematologica</i> , 2020, 105, 640-651.	3.5	32
7	Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. <i>Leukemia</i> , 2020, 34, 1329-1341.	7.2	66
8	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. <i>Blood</i> , 2020, 135, 1759-1771.	1.4	271
9	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. <i>Haematologica</i> , 2020, 105, 2516-2523.	3.5	12
10	Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints. <i>Blood</i> , 2020, 136, 29-29.	1.4	2
11	The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network. <i>Cancer Epidemiology</i> , 2019, 59, 236-243.	1.9	14
12	Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK's population-based Haematological Malignancy Research Network. <i>British Journal of Haematology</i> , 2019, 185, 781-784.	2.5	19
13	The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. <i>Blood</i> , 2019, 133, 1325-1334.	1.4	53
14	Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. <i>International Journal of Epidemiology</i> , 2018, 47, 700-700g.	1.9	47
15	Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. <i>Blood Advances</i> , 2018, 2, 2079-2089.	5.2	18
16	A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population-Based Observational Data. <i>Value in Health</i> , 2018, 21, 1176-1185.	0.3	14
17	MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination. <i>Blood</i> , 2018, 132, 4357-4357.	1.4	1
18	Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort. <i>European Journal of Health Economics</i> , 2017, 18, 255-267.	2.8	18

#	ARTICLE	IF	CITATIONS
19	Emergency admission and survival from aggressive non-Hodgkin lymphoma: A report from the UK's population-based Haematological Malignancy Research Network. <i>European Journal of Cancer</i> , 2017, 78, 53-60.	2.8	22
20	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	2.7	15
21	Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN). <i>Cancer Causes and Control</i> , 2016, 27, 1019-1026.	1.8	46
22	Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15. <i>Cancer Epidemiology</i> , 2016, 42, 186-198.	1.9	88
23	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	12.8	94
24	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	2.9	52
25	Is ethnic density associated with health in a context of social disadvantage? Findings from the Born in Bradford cohort. <i>Ethnicity and Health</i> , 2016, 21, 196-213.	2.5	8
26	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2016, 128, 3186-3186.	1.4	14
27	Mutational Profiling of Peripheral Blood and Bone Marrow Samples Discriminates Reactive Monocytosis from Chronic Myelomonocytic Leukaemia. <i>Blood</i> , 2016, 128, 3181-3181.	1.4	0
28	Similarity Search Methods As an Alternative to Sub-Type Characterisation in Aggressive Lymphomas. <i>Blood</i> , 2016, 128, 3052-3052.	1.4	2
29	Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. <i>Blood</i> , 2015, 126, 2362-2365.	1.4	157
30	Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. <i>Cancer Epidemiology</i> , 2015, 39, 1103-1112.	1.9	45
31	The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients. <i>British Journal of Haematology</i> , 2015, 170, 175-178.	2.5	5
32	Measuring expectations of benefit from treatment in acupuncture trials: A systematic review. <i>Complementary Therapies in Medicine</i> , 2015, 23, 185-199.	2.7	32
33	Predicting Time to Treatment in Follicular Lymphoma Using Population-Based Data. <i>Blood</i> , 2015, 126, 3912-3912.	1.4	3
34	Determining disease prevalence from incidence and survival using simulation techniques. <i>Cancer Epidemiology</i> , 2014, 38, 193-199.	1.9	5
35	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	21.4	147
36	Development Of A Cross Platform, 2-Way Gene Expression Classifier To Distinguish Burkitt Lymphoma From DLBCL, and Assessment Of The Potential Impact Of Its Use In Treatment Decision Making. <i>Blood</i> , 2013, 122, 74-74.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Infectious Illness in Children Subsequently Diagnosed With Acute Lymphoblastic Leukemia: Modeling the Trends From Birth to Diagnosis. <i>American Journal of Epidemiology</i> , 2012, 176, 402-408.	3.4	50
38	Illness patterns prior to diagnosis of lymphoma: Analysis of UK medical records. <i>Cancer Epidemiology</i> , 2011, 35, 145-150.	1.9	3
39	A Unified Prognostic Model for Myelodysplastic Syndrome and Acute Myeloid Leukaemia Based on Flow Cytometric Blast Count. <i>Blood</i> , 2011, 118, 1736-1736.	1.4	10
40	Gene Expression Profiling Using the Illumina <i>â€ˆ</i> DASL <i>â€™</i> ™ Platform on RNA Extracted From Formalin Fixed Paraffin Embedded (FFPE) Tissue Identifies Distinct Prognostic Groups In CHOP-R Treated DLBCL. <i>Blood</i> , 2010, 116, 2485-2485.	1.4	1
41	RQ-PCR Provides a Superior Alternative to Immunohistochemistry In Defining Prognostic Groups In DLBCL, and Predicts Treatment Failure with CHOP-R. <i>Blood</i> , 2010, 116, 2484-2484.	1.4	8